143 related articles for article (PubMed ID: 38580786)
1. Minimal clinically important differences in health-related quality of life after treatment with direct-acting antivirals for chronic hepatitis C: ANRS CO22 HEPATHER cohort (PROQOL-HCV).
Abbas M; Patrizia C; Fabienne M; Marc B; Lucia P; Fabrice C; Martin D; Camelia P
Qual Life Res; 2024 Jun; 33(6):1527-1540. PubMed ID: 38580786
[TBL] [Abstract][Full Text] [Related]
2. Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort).
Carrieri P; Bourlière M; Di Beo V; Lusivika-Nzinga C; Ramier C; Antwerpes S; Protopopescu C; Lacombe JM; Pol S; Fontaine H; Mourad A; Carrat F; Duracinsky M; Marcellin F;
Qual Life Res; 2023 Dec; 32(12):3427-3438. PubMed ID: 37587323
[TBL] [Abstract][Full Text] [Related]
3. Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting-results from the German Hepatitis C-Registry (DHC-R).
Ohlendorf V; Schäfer A; Christensen S; Heyne R; Naumann U; Link R; Herold C; Schiffelholz W; Günther R; Cornberg M; Serfert Y; Maasoumy B; Wedemeyer H; Kraus MR
J Viral Hepat; 2021 Aug; 28(8):1206-1218. PubMed ID: 34003549
[TBL] [Abstract][Full Text] [Related]
4. Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort.
Vallet-Pichard A; Correas JM; Dorival C; Zoulim F; Tran A; Bourlière M; Calès P; Guyader D; Bronowicki JP; Larrey D; Hezode C; Loustaud-Ratti V; Gournay J; de Ledinghen V; Asselah T; Ganne N; Metivier S; Chazouillères O; Leroy V; Rosa I; Samuel D; Mathurin P; Cagnot C; Fontaine H; Carrat F; Pol S;
Clin Res Hepatol Gastroenterol; 2021 Jan; 45(1):101459. PubMed ID: 32595103
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus cure from direct-acting antivirals and mortality: Are people with and without a history of injection drug use in the same boat? (ANRS CO22 Hepather cohort).
Barré T; Bourlière M; Parlati L; Ramier C; Marcellin F; Protopopescu C; Di Beo V; Cagnot C; Dorival C; Nicol J; Zoulim F; Carrat F; Carrieri P;
Drug Alcohol Rev; 2024 Mar; 43(3):718-731. PubMed ID: 38133601
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in Egypt.
Youssef NF; El Kassas M; Farag A; Shepherd A
BMC Gastroenterol; 2017 Jan; 17(1):18. PubMed ID: 28109264
[TBL] [Abstract][Full Text] [Related]
7. Male Sexual Dysfunction Among Egyptian Patients with Chronic Hepatitis C Virus Infection Before and After Direct-Acting Antiviral Drugs.
Elshimi E; Morad W; Mohamad NE
J Sex Med; 2019 Mar; 16(3):402-409. PubMed ID: 30846113
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct-acting antivirals agents interferon-free.
Fagundes RN; Ferreira LEVVC; Pace FHL
PLoS One; 2020; 15(8):e0237005. PubMed ID: 32813740
[TBL] [Abstract][Full Text] [Related]
10. Impact of Interferon-Based Treatment on Quality of Life and Work-Related Productivity of Korean Patients with Chronic Hepatitis C.
Ahn SH; Choe WH; Kim YJ; Heo J; Latarska-Smuga D; Kang J; Paik SW
Gut Liver; 2020 May; 14(3):368-376. PubMed ID: 31533395
[TBL] [Abstract][Full Text] [Related]
11. Psychometric evaluation of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial.
Anderson RT; Baran RW; Erickson P; Revicki DA; Dietz B; Gooch K
Qual Life Res; 2014 Apr; 23(3):877-86. PubMed ID: 24036634
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of direct-acting antivirals for chronic hepatitis C treatment in migrant and non-migrant populations in France.
Djaogol T; Fontaine H; Baudoin M; Protopopescu C; Marcellin F; Dorival C; Simony M; Petrov-Sanchez V; Bourlière M; Delarocque-Astagneau E; Pol S; Carrat F; Carrieri P;
Liver Int; 2021 Oct; 41(10):2328-2340. PubMed ID: 33590608
[TBL] [Abstract][Full Text] [Related]
13. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts.
ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Electronic address: stanislas.pol@aphp.fr
J Hepatol; 2016 Oct; 65(4):734-740. PubMed ID: 27288051
[TBL] [Abstract][Full Text] [Related]
14. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous and post-treatment HCV clearance: relationships with health-related quality of life in HIV infection (ANRS-VESPA2 study).
Marcellin F; Demoulin B; Spire B; Suzan-Monti M; Roux P; Protopopescu C; Sagaon-Teyssier L; Duracinsky M; Dray-Spira R; Carrieri MP;
Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):701-13. PubMed ID: 25723557
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication.
Younossi ZM; Stepanova M; Younossi I; Papatheodoridis G; Janssen HLA; Agarwal K; Nguyen MH; Gane E; Tsai N; Nader F
Liver Int; 2019 Oct; 39(10):1837-1844. PubMed ID: 31173468
[TBL] [Abstract][Full Text] [Related]
17. Direct-acting antivirals for chronic hepatitis C.
Jakobsen JC; Nielsen EE; Feinberg J; Katakam KK; Fobian K; Hauser G; Poropat G; Djurisic S; Weiss KH; Bjelakovic M; Bjelakovic G; Klingenberg SL; Liu JP; Nikolova D; Koretz RL; Gluud C
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012143. PubMed ID: 28922704
[TBL] [Abstract][Full Text] [Related]
18. What Are the Minimum Clinically Important Differences in SF-36 Scores in Patients with Orthopaedic Oncologic Conditions?
Ogura K; Yakoub MA; Christ AB; Fujiwara T; Nikolic Z; Boland PJ; Healey JH
Clin Orthop Relat Res; 2020 Sep; 478(9):2148-2158. PubMed ID: 32568896
[TBL] [Abstract][Full Text] [Related]
19. Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH).
Mora M; Goodyear T; Marcellin F; Shoveller J; Di Beo V; Calzolaio C; Sogni P; Wittkop L; Zucman D; Poizot-Martin I; Lacombe K; Salmon-Céron D; Knight R; Carrieri P
J Viral Hepat; 2020 Dec; 27(12):1462-1472. PubMed ID: 32810905
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.
Evon DM; Sarkar S; Amador J; Lok AS; Sterling RK; Stewart PW; Reeve BB; Serper M; Reau N; Rajender Reddy K; Di Bisceglie AM; Nelson DR; Golin CE; Lim JK; Fried MW
J Hepatol; 2019 Sep; 71(3):486-497. PubMed ID: 31096006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
